Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Varian Medical (VAR) Misses on Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Year-over-year decline in Varian Medical's (VAR) proton therapy segment is the primary cause behind the company's lackluster fourth-quarter performance.
GNC Holdings (GNC) Lags Q3 Earnings & Revenues, Margins Down
by Zacks Equity Research
GNC Holdings (GNC) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from the recent hurricanes and lower sales at the U.S. & Canada and manufacturing/wholesale segments.
Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag
by Zacks Equity Research
Cardiovascular Systems' (CSII) Q1 revenues declined year over year owing to the decline in revenues at both the segments.
Boston Scientific's (BSX) Q3 Earnings In Line, Guidance Up
by Zacks Equity Research
Despite back-to-back natural disasters, Boston Scientific managed to register strong year-over-year increase in both earnings and revenues in the third quarter on balanced growth across all segments.
McKesson (MCK) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
McKesson (MCK) reported strong second-quarter numbers owing to stable performance from Distribution Solutions business.
The Zacks Analyst Blog Highlights: Lockheed Martin, 3M, T-Mobile, Broadcom and Intuitive Surgical.
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Lockheed Martin, 3M, T-Mobile, Broadcom and Intuitive Surgical.
Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up
by Zacks Equity Research
On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.
LabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance
by Zacks Equity Research
Banking on strong third-quarter show and considering a gradually improving foreign exchange scenario, LabCorp (LH) increased its earlier provided 2017 outlook.
Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View
by Zacks Equity Research
Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q4 on continued prescription growth and strength in the Retail Pharmacy USA division.
Baxter (BAX) Beats on Earnings & Sales in Q3, 2017 View Up
by Zacks Equity Research
Baxter (BAX) exited the third quarter on a solid note, courtesy of stellar performances by the company's hospital products and renal segments.
NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut
by Zacks Equity Research
NuVasive's robust top-line growth in Q3 was driven by strong international performance. However, U.S. sales declined on procedural volume challenges and an adverse impact of the recent natural disasters.
Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) rides high on its product and service segments in Q1.
Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance
by Zacks Equity Research
Illumina (ILMN) rides high on sequencing consumables and instruments as well as microarray portfolios in Q3 earnings.
Abaxis (ABAX) Posts In-Line Earnings in Q2, Lags Revenues
by Zacks Equity Research
Abaxis (ABAX) misses the Zacks Consensus Estimate for revenues due to softness in the medical market in Q2. Weak margins are a concern as well.
Edwards Lifesciences (EW) Q3 Earnings, Sales Lag, View Intact
by Zacks Equity Research
Edwards Lifesciences (EW) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from recent natural disasters in the Caribbean and the United States.
Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical (ISRG) posted solid numbers in the third quarter, courtesy of rising customer adoption of procedures and growth in system placements.
This Week's Amazing Earnings Charts
by Tracey Ryniec
Don't look now, but these 5 companies have some of the best earnings track records and charts this week.
Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings?
by Zacks Equity Research
We believe that the growing adoption of Intuitive Surgical's (ISRG) da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the quarter.
Varian Medical Initiates Treatment Using Halcyon System
by Zacks Equity Research
Varian Medical (VAR) has been taking initiatives to gain customers for its broad spectrum of products.
Mazor Robotics Gets CE Mark for Surgical Assurance Platform
by Zacks Equity Research
Earlier this year, Mazor Robotics (MZOR) had announced the receipt of FDA clearance for its Mazor X Align software.
Intuitive Surgical (ISRG) Well Poised on Procedural Business
by Zacks Equity Research
Intuitive Surgical's (ISRG) strong sales growth will continue to be aided by focus on da Vinci system and procedural growth from general surgery, oncology, urology and gynecology.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.
The Zacks Analyst Blog Highlights: Facebook, Air Liquide and Intuitive Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Air Liquide and Intuitive Surgical
Watch Out for the Three Stooges: Global Week Ahead
by John Blank
Q2's biggest earnings week, minutes from the latest FOMC meeting and U.S. GDP Friday may be the Three Musketeers charging markets higher... or, they may become the Three Stooges instead.
Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical posted solid numbers in the quarter under review, courtesy of rising customer adoption of procedures and growth in system placements.